← Back to Patent Explorer
US3868445A Expired / Lapsed US ⏱️ 0.0 years remaining

Dosage unit containing a substance showing a topical effect on the eye, and a method of preparing same

Assignee: Pfizer Health AB
•
Filing: 1973-11-16
•
Granted: 1975-02-25
•
Expires: 1993-11-16
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A method for medicating the eye with a composition in the form of a solid shaped body adapted for insertion in the cavity of the eye and containing a substance having a topical effect on the eye, which composition comprises a mixture of 5 - 90 % of at least one lipophilic substance having a melting point of 37* 75*C, 0 - 40 % of at least one water-soluble or water-swellable polymer in solid, finely-divided form, 0.05 - 30 % of at least one drug having a topical effect on the eye and 0.2 - 20 % of at least one water-insoluble lipophilic polymer having a softening temperature exceeding 70*C and a melting point exceeding 85*C and which is soluble in the lipophilic substance or substances in molten form to serve as stabilizer for the mixture, the percentages relating to percent by weight calculated on the total weight of the mixture.

Inventors

  • 👤 Emma Marta Ryde
  • 👤 Jan Erik Ekstedt

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-24 15:57
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0048; A61K9/0051

Claims Analysis

Total Claims: 5
Claim 1
Independent Claim 327 words
THE METHOD OF MEDICATING THE EYE WITH OPHTHALMIC MEDICATION THE IMPROVEMENT WHICH INCLUDES THE STEP OF PLACING BENEATH ONE EYELID A SOLID SHAPED BODY HAVING A LARGEST DIMENSION BETWEEN THE LIMITS OF 2 - 20 MM AND REMAINING DIMENSIONS WITHIN THE RANGE OF 0.5 - 10 MM, WITH SOFTLY ROUNDED CORNERS SO AS NOT TO CAUSE EYE IRRITATION, THE BODY BEING EITHER PLANAR OR SUITABLY MOLDED TO OBTAIN THE SHAPE OF A LENS CAPABLE OF FITTING INTO THE SPACE BETWEEN THE EYE AND THE SURROUNDING TISSUE WITH A SURFACE FACING TOWARD THE EYE, SAID SOLID SHAPED BODY AS A RESULT OF ITS PLASTICITY FORMING ITSELF TO THE SHAPE OT THE EYE CAVITY WHEN INSERTED INTO THE EYE, SAID BODY COMPRISING A MIXTURE OF: A. 5 - 90% OF AT LEAST ONE LIPOPHILIC SUBSTANCE HAVING A MELTING POINT OF 37*-75*C AND BEING SELECTED FROM THE GROUP CONSISTING OF PARPFFIN, BEES WAX AND GLYCEROL ESTERS OF 8 - 22 CARBON ATOM FATTY ACIDS HAVING MELTING POINTS WITHIN THE AFOREMENTIONED RANGE, B. 0 - 40% OF AT LEAST ONE WATER-SOLUBLE OR WATER-SWELLABLE POLYMER SELECTED FROM THE GROUP CONSISTING OF DEXTRAN, LOWER HYDROXY-ALKYL DEXTRAN, CARNOXY-METHYL OF DEXTRAN, LOWER HYDROXY-ALKYL CELLULOSE, LOWER ALKYL-CELLULOSE, CARBOXYMETHYL CELLULOSE, POLYVINYL ALCOHOL, DEXTRIN, STARCH, POLYVINYL PRYROLLIDONE AND POLYALKYLENE GLYCOLS, IN SOLID FINELY-DIVIDED FORM HAVING A PARTICLE SIZE LESS THAN OPPROXIMATELY 150 MICRONS. C. 0.05 - 20% OF AT LEAST ONE DRUG SHOWING A TOPICAL EFFECT ON THE EYE WITH A PARTICLE SIZE LESS THAN APPROXIMATELY 150 MICRONS, AND D. 0.2 - 20% OF AT LEAST ONE WATER-INSOLUBLE LIPOPHILIC POLYMER HAVING A SOFTENING TEMPERATURE EXCEEDING 70*C AND HAVING A MELTING POINT EXCEEDING 85*C AND WHICH IS SOLUBLE IN THE LIPOPHILIC SUBSTANCE OR SUBSTANCES IN MOLTEN FORM TO SERVE AS STABLIZER FOR THE MIXTURE, SAID POLYMER BEING SELECTED FROM THE GROUP CONSISTING OF POLYVINYL ACETATE, ETHYLENEVINYLACETATE-COPOLYMER, POLYBUTYL METHACRYLATE, POLYETHYLENE, POLYPROPYLENE, ETHYLENEPROPYLENE-COPOLYMER AND MIXTURES THEREOF, THE PERCENTAGES RELATING TO PERCENT BY WEIGHT CALCULATED ON THE TOTAL WEIGHT OF THE MIXTURE.
Claim 2
Independent Claim 327 words
THE METHOD OF MEDICATING THE EYE WITH OPHTHALMIC MEDICATION THE IMPROVEMENT WHICH INCLUDES THE STEP OF PLACING BENEATH ONE EYELID A SOLID SHAPED BODY HAVING A LARGEST DIMENSION BETWEEN THE LIMITS OF 2 - 20 MM AND REMAINING DIMENSIONS WITHIN THE RANGE OF 0.5 - 10 MM, WITH SOFTLY ROUNDED CORNERS SO AS NOT TO CAUSE EYE IRRITATION, THE BODY BEING EITHER PLANAR OR SUITABLY MOLDED TO OBTAIN THE SHAPE OF A LENS CAPABLE OF FITTING INTO THE SPACE BETWEEN THE EYE AND THE SURROUNDING TISSUE WITH A SURFACE FACING TOWARD THE EYE, SAID SOLID SHAPED BODY AS A RESULT OF ITS PLASTICITY FORMING ITSELF TO THE SHAPE OT THE EYE CAVITY WHEN INSERTED INTO THE EYE, SAID BODY COMPRISING A MIXTURE OF: A. 5 - 90% OF AT LEAST ONE LIPOPHILIC SUBSTANCE HAVING A MELTING POINT OF 37*-75*C AND BEING SELECTED FROM THE GROUP CONSISTING OF PARPFFIN, BEES WAX AND GLYCEROL ESTERS OF 8 - 22 CARBON ATOM FATTY ACIDS HAVING MELTING POINTS WITHIN THE AFOREMENTIONED RANGE, B. 0 - 40% OF AT LEAST ONE WATER-SOLUBLE OR WATER-SWELLABLE POLYMER SELECTED FROM THE GROUP CONSISTING OF DEXTRAN, LOWER HYDROXY-ALKYL DEXTRAN, CARNOXY-METHYL OF DEXTRAN, LOWER HYDROXY-ALKYL CELLULOSE, LOWER ALKYL-CELLULOSE, CARBOXYMETHYL CELLULOSE, POLYVINYL ALCOHOL, DEXTRIN, STARCH, POLYVINYL PRYROLLIDONE AND POLYALKYLENE GLYCOLS, IN SOLID FINELY-DIVIDED FORM HAVING A PARTICLE SIZE LESS THAN OPPROXIMATELY 150 MICRONS. C. 0.05 - 20% OF AT LEAST ONE DRUG SHOWING A TOPICAL EFFECT ON THE EYE WITH A PARTICLE SIZE LESS THAN APPROXIMATELY 150 MICRONS, AND D. 0.2 - 20% OF AT LEAST ONE WATER-INSOLUBLE LIPOPHILIC POLYMER HAVING A SOFTENING TEMPERATURE EXCEEDING 70*C AND HAVING A MELTING POINT EXCEEDING 85*C AND WHICH IS SOLUBLE IN THE LIPOPHILIC SUBSTANCE OR SUBSTANCES IN MOLTEN FORM TO SERVE AS STABLIZER FOR THE MIXTURE, SAID POLYMER BEING SELECTED FROM THE GROUP CONSISTING OF POLYVINYL ACETATE, ETHYLENEVINYLACETATE-COPOLYMER, POLYBUTYL METHACRYLATE, POLYETHYLENE, POLYPROPYLENE, ETHYLENEPROPYLENE-COPOLYMER AND MIXTURES THEREOF, THE PERCENTAGES RELATING TO PERCENT BY WEIGHT CALCULATED ON THE TOTAL WEIGHT OF THE MIXTURE.
Claim 3
Dependent Claim 23 words
The method according to claim 1 wherein the solid shaped body has a largest dimension lying between the limits 6 and 16 mm.
Claim 4
Dependent Claim 18 words
The method according to claim 1 wherein at least one surface of the solid shaped body is convex.
Claim 5
Dependent Claim 43 words
The method according to claim 1, wherein the drug showing topical effect on the eye is selected from the group consisting of pilocarpine, atropine, metaoxedrin, adrenaline, physostigmine, synstigmine, guanetidine, ascorbic acid, chloramphenicol, sulfamethizole, hydrocortisone, and, in suitable cases, salts thereof, and mixtures thereof.

References Cited (Backward Citations)

US3670065A Cited
US3618604A Cited
US3630200A Cited
US3641237A Cited
US3710796A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1978-02-24 1978-08-26 1979-02-25 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1982-02-24 1982-08-26 1983-02-25 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1986-02-24 1986-08-26 1987-02-25 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag